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ABSTRACT
Esophageal squamous cell carcinoma (ESCC) is one of the most lethal malignancies 
of the digestive tract in East Asian countries. Multimodal therapies, including adjuvant 
chemotherapy and neo-adjuvant chemotherapy, have become more often used for 
patients with advanced ESCC. However, the chemotherapy effect is often limited by 
patients’ drug resistance. This study demonstrated that EIF5A2 (eukaryotic translation 
initiation factor 5A2) overexpression induced stemness and chemoresistance in ESCC 
cells. We showed that EIF5A2 overexpression in ESCC cells resulted in increased 
chemoresistance to 5-fluorouracil (5-FU), docetaxel and taxol. In contrast, shRNAs 
suppressing eIF5A2 increased tumor sensitivity to these chemotherapeutic drugs. 
In addition, EIF5A2 overexpression was correlated with a poorer overall survival in 
patients with ESCC who underwent taxane-based chemotherapy after esophagectomy 
(P < 0.05). Based on these results, we suggest that EIF5A2 could be a predictive 
biomarker for selecting appropriate chemo-treatment for ESCC patients and EIF5A2 
inhibitors might be considered as combination therapy to enhance chemosensitivity 
in patients with ESCC.
INTRODUCTION
Esophageal squamous cell carcinoma (ESCC) 
is the seventh most common cancer and the fifth most 
common cause of cancer-related death in the world [1]. 
Esophagectomy remains the mainstay of treatment for 
resectable disease. However, the prognosis for patients 
treated by surgery alone is poor. Recent developments 
in postoperative management, including chemotherapy 
and fractionized radiation therapy, have contributed to 
improvements in the surgical outcome [2–4]. Because 
chemotherapy is useful as adjuvant therapy before or 
after surgery for potentially resectable tumors, it has led 
to considerable interest in the identification of predictive 
biomarkers for selecting appropriate treatments for 
patients with ESCC.
Our previous study demonstrated that chromosomal 
amplification and hypoxia could induce the expression 
of EIF5A2, the eukaryotic translation initiation factor 
5A2, and that it was important in epithelial-mesenchymal 
transition (EMT) and metastasis of ESCC [5]. Recently, 
the ablation or inhibition of EIF5A2 was also reported 
to enhance the chemosensitivity of HCC (hepatocellular 
carcinoma) cells to 5-fluorouracil (5-FU)/doxorubicin and 
breast cancer cells and bladder cancer cells to doxorubicin 
[6–9]. Despite these reports, the underlying mechanism of 
acquired chemosensitivity of silencing EIF5A2 is poorly 
defined. Because chemotherapy is becoming more widely 
used as adjuvant therapy for patients with ESCC, a better 
understanding of the mechanisms of chemoresistance 
of EIF5A2 is therefore critical for selecting treatments 
and the development of potential strategies to overcome 
chemoresistance.
In this study, we sought to explore the role of 
EIF5A2 in the chemoresistance of ESCC cells, and we 
tested the chemosensitivity in both EIF5A2 overexpressed 
cells and knock-down cells. In addition, EIF5A2 
overexpression enhanced the stemness of ESCC cells 
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and inhibited the apoptosis activated by chemotherapy 
treatment. Moreover, our results show that the EIF5A2 
expression in resected ESCC specimens is correlated 
with a worse clinical outcome and response to adjuvant 
chemotherapy, suggesting an important clinical application 
of EIF5A2 in selecting appropriate chemo-treatments for 
patients with ESCC.
RESULTS
EIF5A2 increased the stemness of ESCC cells
Our previous study showed that EIF5A2 
introduction could increase the tumorigenicity of ESCC 
cells in vivo and in vitro [5]. To determine whether 
EIF5A2 introduction is sufficient to enhance the stemness 
of ESCC cells, the eIF5A2 and vector stably transfected 
KYSE510 cells were established, and sphere assays were 
performed. The sphere-forming ability of 510-eIF5A2 
cells was significantly increased (P < 0.05) compared to 
that of vector control cells (510-Vec) (Figure 1A and 1B), 
suggesting that EIF5A2 increased self-renewal ability.
Then, we extended our analysis by examining 
the expression levels of stemness-associated genes by 
qRT-PCR on EIF5A2 overexpressed cells. The RNA 
levels of nanog [10], p75NTR [11], OCT-4 [12], CD24 
[13] and CD44 [14] increased in the range of 2.8-fold 
(p75NTR) up to 11-fold (nanog) in EIF5A2 overexpressed 
KYSE510 cells (510-eIF5A2) compared with vector 
control cells (P < 0.01; Figure 1C). Similar results were 
also observed in EIF5A2 overexpressed KYSE410 cells 
(410-eIF5A2) (Figure 1A and 1D). Taken together, these 
findings revealed that EIF5A2 overexpression increased 
the stemness of ESCC cells. The RNA level of ABCG2 
(ATP-binding cassette, sub-family G, member 2) [15], a 
multiple drug-resistant transporter gene, also increased by 
1.6-fold in 510-eIF5A2 and 5.9-fold in 410-eIF5A2 cells 
(P < 0.01; Figure 1C and 1D). The protein levels of nanog, 
p75NTR, CD24, CD44 and ABCG2 increased in varying 
degrees in EIF5A2 overexpressed cells (510-eIF5A2 and 
410-eIF5A2) compared with their respective vector control 
cells (Figure 1E and 1F).
Chemoresistance induced by EIF5A2 
overexpression
Because drug resistance is one of the characters of 
cancer stem cells and a multiple drug-resistant transporter 
gene increased in the EIF5A2 overexpressed cells, we next 
investigated whether EIF5A2 overexpression contributes 
to the chemoresistance of ESCC cells. For this purpose, 
XTT assays were used to evaluate the chemoresistance 
between EIF5A2 overexpressed KYSE510 cells 
(510-eIF5A2) and vector control cells (510-Vec). The 
510-eIF5A2 cells were more resistant to 5-FU than the 
vector cells (Figure 2A). The results demonstrated that 
510-eIF5A2 cells were more resistant to docetaxel and 
taxol than 510-Vec cells (Figure 2A). To rule out the 
possibility that the resistance of chemotherapy induced 
by EIF5A2 overexpression is specific to KYSE510 and 
its derivative cells, another ESCC cell line, KYSE410, 
was next studied. Similar results were observed in the 
410-eIF5A2 cells and 410-Vec cells (Figure 2B).
Chemo-sensitivity increased by EIF5A2 silencing
We next examined whether silencing EIF5A2 
expression would increase the chemo-sensitivity by 
knocking down EIF5A2 expression in KYSE180 and 
EC109 cells. The ESCC cells were transduced with 
lentivirus containing shRNAs (sh1 and sh2) against 
eIF5A2 (Figure 3A), and cytotoxicity assays were 
carried out. It was found that KYSE180 with reduced 
EIF5A2 expression were more sensitive to 5-FU, 
docetaxel and taxol than the vector control cells (Figure 
3B, 3C). Similar results were observed in EC109 cells 
(Figure 3D, 3E and 3F).
EIF5A2 conferred chemoresistance by inhibiting 
apoptosis in ESCC cells
We next elucidated whether EIF5A2 accounts for 
chemoresistance through inhibiting apoptosis. 510-eIF5A2 
cells and 510-Vec cells were treated with 5-FU, docetaxel 
and taxol, and in situ TUNEL assays were performed. 
As shown in Figure 4A, the number of apoptotic cells 
decreased in 510-eIF5A2 cells compared with 510-Vec 
cells. Similar results were obtained in KYSE410 derived 
cells (Figure 4B). In contrast, KYSE180 transduced with 
shRNA suppressing eIF5A2 (180-sh1) and vector control 
cells (180-Vec) were also treated with chemotherapeutic 
reagents, and the in situ TUNEL results also indicated 
an increased apoptotic response toward 5-FU, docetaxel 
and taxol in EIF5A2 knock-down cells compared with 
vector control cells (Figure 4C). Similar results were 
also obtained in EC109-derived cells (Figure 4D). These 
findings support that the preferential survival of EIF5A2 
overexpressed cells after chemotherapy reagents was 
attributed to low rates of apoptosis. The activation of 
PARP and caspase-8, two typical characteristics of cell 
apoptosis, was also investigated by western blotting 
in EIF5A2 overexpressed cells and silenced cells. As 
shown in Figure 5A, the cleaved PARP and caspase-8 
were decreased in the 510-eIF5A2 cells compared with 
510-Vec cells after treatment with 5-FU, docetaxel and 
taxol. In addition, overexpression of eIF5A2 in KYSE410 
significantly decreased the cleaved PARP in comparison 
with the vector control cells (Figure 5B). As shown in 
Figure 5C, EIF5A2 knock-down resulted in an increase 
of PARP and caspase-8 activation in KYSE180 cells after 
treatment with 5-FU, docetaxel and taxol. Additionally, 
EIF5A2 knock-down resulted in an activation of PARP 
in EC109 cells treated with 5-FU, docetaxel and taxol 
(Figure 5D).
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EIF5A2 overexpression correlated with 
a poorer outcome of chemotherapy
To further explore the role of EIF5A2 in 
chemoresistance in clinical samples, we evaluated the 
expression of EIF5A2 by IHC in patients who underwent 
taxane-based chemotherapy after esophagectomy. Positive 
staining of EIF5A2 was detected in 40 of 89 (44.94%) 
tumor tissues and negative staining was detected in 49 
of 89 (55.06%) tumor cases (Figure 6A). The association 
study demonstrated that EIF5A2 expression was not 
significantly associated with gender, age, differentiation 
status or T status, but it was significantly associated 
with N status (P = 0.011) (Table 1). The Kaplan-Meier 
survival analysis revealed that EIF5A2 expression was 
correlated with poorer overall survival (OS) in patients 
who underwent postoperative taxane-based chemotherapy 
(log-rank test, P = 0.047) (Figure 6B). The mean OS time 
Figure 1: EIF5A2 overexpression increased the stemness of ESCC cells. A. The protein level was determined in EIF5A2 
overexpressed cells (510-eIF5A2 and 410-eIF5A2) and vector control cells (510-Vec and 410-Vec) by western blotting assay. Tubulin was 
used as loading control. B. Representative pictures showing increased sphere-forming ability in 510-eIF5A2 compared with 510-Vec cells. 
The results are summarized as the mean ± SEM of three independent assays. C, D. Relative expression of stemness-associated genes (nanog, 
p75NTR and OCT-4), surface antigens associated with ESCC cancer stem cells (CD24 and CD44) and multi drug-resistant transporter gene 
(ABCG2) were compared by qRT-PCR between EIF5A2 overexpressed cells (510-eIF5A2 and 410-eIF5A2) and corresponding vector 
control cells. E, F. The protein levels of nanog, p75NTR, CD24, CD44, ABCG2 increased in EIF5A2 overexpressed cells (510-eIF5A2 and 
410-eIF5A2) compared with vector control cells (510-Vec and 410-Vec). Actin was set as loading control.
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of the EIF5A2(–) and EIF5A2(+) groups were 62.08 
months (95% CI: 52.03–72.14) and 47.77 months (95% 
CI: 35.97–59.58), respectively.
DISCUSSION
ESCC is one of the most lethal malignancies of the 
digestive tract in East Asian countries. Often, when many 
cases are initially diagnosed, the malignancy is already in 
an advanced stage. Multimodal therapies are necessary 
to prolong the survival of patients with ESCC. Adjuvant 
chemotherapy and neo-adjuvant chemotherapy have 
become the first-line therapy for patients with advanced 
ESCC [4]. However, the effectiveness of chemotherapy is 
often limited by drug resistance of the patients. Therefore, 
it is very important to screen predictive biomarkers for 
chemosensitivity to select appropriate regimens for 
patients with ESCC.
Overexpression of EIF5A2 has been detected 
in many solid tumors, including ovarian cancer [16], 
hepatocellular carcinoma [17, 18], non-small cell 
lung cancer [19], bladder cancer [20], melanoma [21], 
colorectal cancer [22], pancreatic adenocarcinoma [23] 
and ESCC [5]. It was also reported that EIF5A2 could 
promote tumor metastasis and angiogenesis in ESCC and 
hepatocellular carcinoma [5, 6, 18]. Our previous studies 
found that EMT was involved in the above processes 
[5, 18]. Because EMT is not only a process to acquire 
metastasis but also a complicated reprogramming process 
through which differentiated epithelial cells reverse to an 
undifferentiated state by acquiring stem cell-like function 
[24], we tested whether forced expression of EIF5A2 
could endow the cells with stem cell properties. Our 
results indicated that EIF5A2 overexpression enhanced the 
stemness of the 510-eIF5A2 cells and induced multiple 
cancer stem cell markers.
Cancer stem cells are supposed to be responsible 
for not only tumor initiation and maintenance but also 
resistance to chemotherapy, radiotherapy and early 
recurrence. We previously reported that shRNAs 
suppressing eIF5A2 combined with chemotherapeutic 
reagent effectively reduced the volume and weight 
of xenografts in nude mice [5]. Additionally, some 
in vitro studies reported that knock-down or inhibition 
of EIF5A2 enhanced the chemosensitivity of HCC 
cells to 5-FU/ doxorubicin and breast cancer cells and 
bladder cancer cells to doxorubicin [6–9]. Because 
adjuvant therapy has been increasingly used in the 
treatment of advanced ESCC, we tested whether 
EIF5A2 induced chemoresistance of ESCC cells. The 
overexpression of eIF5A2 in the ESCC cells (KYSE510 
and KYSE410) led to increased chemoresistance to 
5-FU, docetaxel and taxol; whereas shRNA-mediated 
silencing of eIF5A2 in the ESCC cells (KYSE180 
and EC109) increased chemosensitivity towards these 
chemotherapeutic agents.
Figure 2: EIF5A2 overexpression induced chemoresistance in ESCC cells. A. 510-eIF5A2 cells are more chemoresistant than 
510-Vec cells at individual doses of 5-FU, docetaxel and taxol, as shown by XTT assay. *, P < 0.05; **, P < 0.01. B. 410-eIF5A2 cells are 
more chemoresistant than 410-Vec cells at individual doses of 5-FU, docetaxel and taxol, as shown by XTT assay. *, P < 0.05; **, P < 0.01.
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Cancer stem cell chemoresistance is explained 
by slow cycling, efflux of drugs by ATP binding 
cassette transporters and upregulation of anti-apoptosis 
[25, 26]. Our study found that the RNA and protein levels 
of ABCG2 were increased in EIF5A2 overexpressed 
cells. ABCG2 is an important member of the ABC 
transporter superfamily that has been suggested to be 
involved in multidrug resistance in cancer [27]. It has 
a diverse range of substrates, including doxorubicin, 
imatinib, and mitoxantrone [28]. This result is consistent 
with the previous findings that silencing or inhibition of 
EIF5A2 led to sensitization of some cancer cells toward 
doxorubicin [7–9].
5-FU is widely used in cancer chemotherapy. It 
inhibits thymidylate synthase, an essential enzyme for 
the de novo synthesis of thymidylate and subsequently 
DNA synthesis. This results in imbalance of dTTP/
dUTP and DNA damage. Both the imbalance and DNA 
damage lead to apoptosis [29]. It was also reported 
that silencing of endogenous EIF5A2 increased tumor 
perfusion by remodeling tumor vessels, thus increased 
the chemosensitivity of HCC cells to 5-FU in vivo [6]. 
In this study, western blotting assay demonstrated that 
overexpression of EIF5A2 reduced the activation of PARP 
and caspase-8 after treatment with chemotherapeutics; in 
contrast, knock-down of EIF5A2 increased the PARP and 
Figure 3: Knock-down of eIF5A2 increased chemosensitivity. A. Knock-down of eIF5A2 by shRNAs (sh1 and sh2) compared 
with vector control was confirmed in KYSE180 cells by western blotting analysis. Tubulin was set as loading control. B, C. The eIF5A2 
knock-down cells (180-sh1 and 180-sh2) were significantly more sensitive than the vector cells at individual 5-FU (B), docetaxel and taxol 
(C) doses. *, P < 0.05; **, P < 0.01. D. Knock-down of eIF5A2 was confirmed in EC109 cells by western blotting analysis. Tubulin was 
set as loading control. E. F. The eIF5A2 knock-down EC109 cells were significantly more sensitive than the vector cells at individual 5-FU 
(E), docetaxel and taxol (F) doses. *, P < 0.05; **, P < 0.01.
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caspase-8 activation in comparison with the vector control 
cells. These findings support the role of anti-apoptosis in 
the gain and manifestation of chemoresistance conferred 
by EIF5A2 in ESCC cells.
Long-term survival of patients with ESCC is poor 
due to high rates of therapeutic failure and tumor relapse. 
Discovering reliable chemosensitivity markers that could 
accurately predict clinical outcome is beneficial. In our 
study, the Kaplan-Meier analysis indicated that EIF5A2 
expression was associated with a poorer survival in patients 
with ESCC who underwent taxane-based chemotherapy 
after esophagectomy. Based on our results, we believe that 
inhibition of EIF5A2 could be a highly effective strategy 
in overcoming 5-FU or taxane-based chemoresistance in 
a clinical setting. N1-guanyl-1, 7-diaminoheptane (GC7), 
which inhibits EIF5A2 activation [8], could be considered 
as a combination therapy to enhance chemosensitivity in 
patients with ESCC.
MATERIALS AND METHODS
Patients and tissue samples
Between December 2004 and August 2009, a 
retrospective cohort of 89 patients with ESCC who 
underwent esophagectomy with adjuvant chemotherapy at 
Sun Yat-sen University Cancer Center was enrolled in this 
study. The patients were diagnosed with primary ESCC, 
and none of them had received preoperative chemotherapy, 
preoperative radiotherapy, or concurrent chemoradiotherapy. 
Figure 4: in situ cell death assay showed the effect of EIF5A2 on chemoresistance of ESCC cells. After treatment with 
5-FU, docetaxel and taxol for 48 h, in situ TUNEL assays were performed on cells. Representative images of TUNEL assay are shown. The 
apoptotic cells were stained a brown color, and the nuclei were counterstained with hematoxylin. EIF5A2 overexpressed 510 A. and 410 
B. cells showed fewer apoptotic cells than their respective vector controls, whereas eIF5A2 knock-down increased apoptotic cells in 180 
C. and EC109 cells D. compared with their respective vector controls (original magnification: 20×). Summary of apoptotic cells ratio (/Vec) 
was shown (right). *, P < 0.05; **, P < 0.01.
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Figure 5: EIF5A2 conferred chemoresistance by inhibiting apoptosis. A. Cleaved PARP and Caspase-8 were found to be 
inhibited in EIF5A2 overexpressed 510 cells in response to 5-FU (50 μM), docetaxel (0.02 μM) and taxol (0.001 μM) when analyzed by 
western blotting analysis. B. Activation of PARP was inhibited in 410-eIF5A2 cells when treated with 5-FU (5 μM), docetaxol (0.01 μM) 
and taxol (0.0075 μM) compared with 410-Vec cells. C. Cleaved PARP and Caspase-8 were increased in eIF5A2 knock-down 180 cells 
treated with 5-FU (60 μM), docetaxel (0.01 μM) and taxol (0.003 μM) compared with 180-Vec cells. D. Activation of PARP was increased 
in EC109-sh cells when treated with 5-FU (50 μM), docetaxel (0.015 μM) and taxol (0.007 μM) compared with vector control cells. Tubulin 
or actin was set as loading control.
Figure 6: EIF5A2 expression correlated with a poorer outcome of chemotherapy. A. The representative images of EIF5A2 
negative and positive expression in ESCC tissues (original magnification: 20×). B. Kaplan-Meier analysis indicated that the overall survival 
rate of patients with ESCC who received postoperative taxane-based chemotherapy was significantly decreased in the EIF5A2(+) group 
compared with the EIF5A2(–) group (P = 0.047).
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Staging was uniformly defined using the criteria set forth 
by the 6th edition of American Joint Committee on Cancer 
Guidelines. Of the 89 patients who received taxane-based 
chemotherapy, 62 (69.7%) underwent taxol-based regimens 
and 27 (30.3%) underwent docetaxel-based regimens. The 
age of the patients ranged from 35 to 72 years at the time 
of surgery (median age: 55 years). The median follow-
up time was 60 months (inverted Kaplan-Meier analysis) 
[30]. Tissue samples used in the study were approved by 
the Committees for Ethical Review of Research Involving 
Human Subjects in Sun Yat-sen University Cancer Center.
Cell lines
ESCC cell lines KYSE510, KYSE180, and 
KYSE410 were obtained from DSMZ, the German 
Resource Center for Biological material [31]. EC109 
was kindly provided by Professor G. Srivastava [32]. 
Cells were maintained in DMEM medium (Gibco 
BRL, NY) supplemented with 10% fetal bovine serum 
(ExCell, Shanghai, China). 293FT cells were purchased 
from Invitrogen (Carlsbad, CA).
Virus production and stable cell lines established
The plenti-eIF5A2 construct was purchased from 
GeneCopoeia (Guangzhou, China). The constructs containing 
shRNAs suppressing eIF5A2 were from Sigma-Aldrich 
company (Shanghai, China). The lentiviruses were packaged 
in 293FT cells according to the manufacturer’s protocol 
(Invitrogen, CA). The stable cell lines (overexpressed or 
knock-down) were established after cells were transduced 
with lentiviruses (plenti-eIF5A2 or shRNAs) and selected 
with puromycin. The concentration of puromycin for the 
cell lines selection was listed as: KYSE510 (1.2 μg/ml), 
KYSE410 (0.6 μg/ml), KYSE180 (0.5 μg/ml) and EC109 
(0.6 μg/ml).
Sphere assay
510-eIF5A2 and vector control cells were seeded into 
24-well polyHEMA-coated plates (Sigma-Aldrich, St Louis, 
MO) and cultured for 2 weeks in DMEM/F12 medium 
supplemented with 4 μg/mL insulin (Bioind, Kibbutz Beit 
haemek, Israel), B27 (Gibco, Grand island, NY), 20 ng/mL 
EGF (PeproTech, Rocky Hill, NJ) and 10 ng/mL basic FGF 
(PeproTech). Cells were replenished with fresh medium 
every second day [33]. The spheres in the suspension culture 
were counted under microscope (Olympus IX71) [34].
Quantitative real-time PCR (qRT-PCR)
Total RNA from cells was extracted using Trizol 
(Invitrogen, CA) according to the manufacturer’s 
Table 1: Correlation between EIF5A2 expression and clinicopathological features of primary 
ESCC





 female 13 7 (53.8%) 6 (46.2%)
 male 76 42 (55.3%) 34 (44.7%)
Age 0.221
 < 57 year 53 32 (60.4%) 21 (39.6%)
 ≥ 57 year 36 17 (47.2%) 19 (52.8%)
Differentiation 0.184
 1–2 62 37 (59.7%) 25 (40.3%)
 3 27 12 (44.4%) 15 (55.6%)
T status 0.119
 T1-T2 15 11 (73.3%) 4 (26.7%)
 T3-T4 74 38 (51.4%) 36 (48.6%)
N status 0.011
 N0 20 16 (80.0%) 4 (20.0%)
 N1 69 33 (47.8%) 36 (52.2%)
Note: The Pearson Chi-Square test was used as statistical analysis. Significant difference was defined when P < 0.05.
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instructions. Reverse transcription was performed using 
the SuperScript reverse transcriptase (Invitrogen, CA). 
The cDNA was subjected to qRT-PCR using the SYBR 
Green reagent (Roche, Mannheim, Germany) and an 
ABI 7900HT Fast Real-time PCR system (Applied 
Biosystems). 18S rRNA was used as internal control. 
The assays were performed in triplicate, and values were 
normalized using the internal control. PCR products 
were subjected to dissociation curve analysis to exclude 
amplification of nonspecific products. Quantitative 
data were analyzed using the ΔCt method. The primer 
sequences are listed in the Supplementary Data.
Western blotting
Cells were lysed with RIPA buffer (Cell signaling 
technology, Danvers, MA), the proteins were fractionated 
by SDS-PAGE and western blotting was performed. The 
blots were incubated with diluted primary antibodies 
overnight at 4°C. Then, blots were exposed to the 
appropriate peroxidase-conjugated secondary antibodies 
(Cell Signaling Technology, MA) at 1:3000 for 2 h at room 
temperature. Finally blots were developed with Luminata 
Crescendo western HRP substrate (Millipore, MA). The 
following antibodies were used: EIF5A2 (1:1000) (Wolwo, 
Shanghai, China), Casepase-8 (1:1000), PARP (1:1000), 
CD44 (1:500), nanog (1:500) and p75NTR (1:500) (Cell 
Signaling Technology, MA), ABCG2 (1:500), CD24 
(1:500), β-tubulin (1:1000) and actin (1:1000) (Santa Cruz 
Biotechnology, TX).
Cytotoxicity assay
The drugs used in the study were: 5-FU (SunRise 
Ltd., Shanghai, China), docetaxel (Aventis Pharma 
S.A., Bridgewater, NJ) and taxol (Wellso Pharma, 
Beijing, China). Chemotherapy-induced cytotoxicity 
was determined using an XTT assay (CCK-8, Dojindo, 
Kyushu, Japan). Cells were plated in 96-well plates at 
the appropriate density. Twenty-four hours later, cells 
were treated with 2-fold diluted concentrations of drugs 
for another 70 hours at 37°C. Then the XTT assay was 
performed and assayed at OD450 according to the 
manufacturer’s instructions. Three independent assays 
were performed.
In situ cell death detection assay
Apoptotic cells were detected using an in situ 
Cell Death Detection Kit (Roche Applied Science, IN) 
according to the protocol. Cells were plated on the cover 
slides and treated with different chemotherapy regents. 
Forty-eight hours later, cells were washed with PBS 
and fixed in 4% paraformaldehyde. After blocking and 
incubation in permeabilisation buffer, apoptotic cells 
were determined by the terminal deoxyribonucleotidyl 
transferase (TdT)-mediated dUTP-digoxigenin nick end 
labeling (TUNEL) assay. Signal was converted by adding 
Concerter-POD and analyzed under light microscope.
Immunohistochemistry (IHC)
IHC was performed using the standard streptavidin-
biotin-peroxidase complex method. Briefly, the tissue 
sections were deparaffinized and subjected to antigen 
retrieval in EDTA antigen retrieval buffer (ZSGB-BIO, 
Beijing, China). Then the sections were incubated with 
the diluted primary antibody EIF5A2 (1:50) (Wolwo, 
Shanghai, China) overnight at 4°C. After incubation with 
horseradish peroxidase-linked secondary antibody (Real 
Envision Detection Kit, Gene Tech, Shanghai, China) for 
30 min, the sections were counterstained with Mayer’s 
hematoxylin. Expression of EIF5A2 was scored as absent 
(total absence of staining), very weak (faint staining in 
< 25% of tumor cells), moderate (moderate staining in ≥ 
25% to < 75%, or strong staining in < 25% of tumor cells), 
and strong (moderate staining in ≥ 75% or strong staining 
in ≥ 25% of tumor cells). In the present study, absent/
very weak staining was defined as negative staining and 
moderate/strong staining as positive staining.
Statistical analysis
Statistical calculations were carried out with the 
SPSS 16.0 software package (SPSS, Inc., Chicago, IL). 
Survival curves were generated according to the Kaplan-
Meier method and log-rank tests. All data were expressed 
as the means ± SEM. The results were considered 
statistically significant when P < 0.05.
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